Adoptive cell transfer with CAR T cells engineered to recognize CD123 cells has been tested in several clinical trials for patients with AML (NCT04230265, NCT03766126, NCT04678336) [4, 8]; however, no conclusive data on safety and efficacy are available thus far, and the improvement of the approach to achieve complete remission (CR) while preventing potential toxicity is still an unmet clinical need. Here, IL3RA is linked to acute myeloid leukemia.